Supplementary Table 1.
Development of Infection and Death in Each of the Study Periods: at Baseline, on Treatment and Post-Treatment
| Variable treatment arm | Baseline infection |
Incident infection |
||||
|---|---|---|---|---|---|---|
| On treatment |
Post-treatment |
|||||
| Prednisolone (n = 547) | No prednisolone (n = 545) | Prednisolone (n = 547) | No prednisolone (n = 545) | Prednisolone (n = 463) | No prednisolone (n = 447) | |
| Deaths | NA | NA | 76 (14) | 98 (18) | 145 (31) | 141 (32) |
| Patients developing an infection | 64 (12) | 71 (13) | 127 (23) | 124 (23) | 56 (12) | 33 (7) |
| Patients developing infection at >1 site | 2 (0.4) | 4 (0.7) | 8 (2) | 10 (2) | 6 (1) | 4 (0.9) |
| Patients developing >1 infection | 0 | 0 | 16 (3) | 12 (2) | 0 | 0 |
NOTE. Values are n (%). Subgroups of patients developing more than 1 infection or at more than 1 site are shown.
NA, not applicable.